证券代码：002019 证券简称：亿帆医药 亿帆医药股份有限公司投资者关系活动记录表 编号：2023002 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | 其他（现场参与+网络视频直播） | | 参与单位名称及 | 现场投资者、线上投资者和参与文字问答的投资者 | | 人员姓名 | | | | 公司董事长兼总裁程先锋先生，副总裁李锡明先生，副总裁耿雨红 女士，董事兼副总裁林行先生，董事兼中药事业部发展业务负责人 | | 上市公司接待人 | 周本余先生，中药事业部创新业务负责人龚群先生，小分子事业部 | | 员姓名 | 负责人钱莉苹女士，国际事业部负责人李佳先生，财务总监喻海霞 | | | 女士，董事、副总裁兼董事会秘书冯德崎先生等 | | 时间 | 2023 年 6 月 2 日 13:00-15:00 | | 地点 | 合肥亿帆生物制药有限公司会议室、全景网"投资者关系互动平台" | | | （https://ir.p5w.net） | | 形式 | 现场+ ...

Financial Performance - The net profit attributable to shareholders decreased by 21.93% after excluding non-recurring gains and losses[16] - Net profit attributable to shareholders of the listed company decreased by 46.59% to ¥64,774,428.20 from ¥121,266,909.58 year-on-year[38] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥59,978,038.28, down 21.93% from ¥76,821,416.28 in the previous year[38] - Basic and diluted earnings per share both decreased by 50.00% to ¥0.05 from ¥0.10 year-on-year[38] Revenue and Cash Flow - The total operating revenue for Q1 2023 was ¥938,532,039.13, representing a 3.60% increase compared to ¥905,920,591.79 in the same period last year[38] - The net cash flow from operating activities increased by 104.44% compared to the same period last year, mainly due to an increase in received payments[16] - The net cash flow generated from operating activities improved significantly to ¥2,042,875.34, compared to a negative cash flow of ¥46,018,343.12 in the same period last year, marking a 104.44% increase[38] - The company reported cash inflows from operating activities of CNY 1,077,790,038.41 in Q1 2023, an increase from CNY 1,007,886,294.93 in the same period last year, representing a growth of approximately 6.9%[58] - The company reported a decrease in cash outflows for operating activities, totaling CNY 1,075,747,163.07 in Q1 2023, compared to CNY 1,053,904,638.05 in Q1 2022, showing improved cash management[58] Assets and Liabilities - Total assets at the end of the reporting period were ¥12,588,862,242.31, a slight increase of 0.36% from ¥12,543,503,416.06 at the end of the previous year[38] - The total current assets increased, with cash and cash equivalents reaching ¥1,214,966,438.53, up from ¥1,143,783,700.15[30] - The total liabilities increased to ¥3,423,082,919.34 from ¥3,397,259,755.63 year-on-year[38] - The company's financial assets decreased by 84.29% to 15,000,000.00 yuan, attributed to the redemption of financial products[40] Expenses and Impairments - Tax and additional charges increased by 54.14% to ¥10,831,847.60, primarily due to VAT and related taxes from inter-company transactions[8] - Other income decreased by 89.32% to ¥4,844,318.49, mainly due to a reduction in government subsidies received[8] - Operating costs rose to ¥480,751,477.19, compared to ¥427,472,846.50 in the same period last year[38] - The company recorded an asset impairment loss increase of 814.24% to ¥-1,221,138.65, mainly due to inventory impairment[19] - The company reported a significant reduction in credit impairment losses by 96.74% to ¥-124,882.34, attributed to the recovery of accounts receivable[8] Investments and Development - Investment income improved by 32.17%, with losses from joint ventures decreasing[8] - Research and development expenses for the period were ¥47,510,975.21, up from ¥38,302,629.24 in the previous year[33] - The company received several drug registration certificates, including for the injection of Sulfate Vincristine and other products, enhancing its product portfolio[25][28] - The company’s subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., received a drug registration certificate for Lacosamide injection on March 10, 2023[48] - The company’s subsidiary, Yiyi Biopharmaceutical Development (Shanghai) Co., Ltd., received a clinical trial approval notice for the product F-652 on March 21, 2023[50] Financing Activities - Total cash inflow from financing activities was $1,112,952,122.70, compared to $814,866,505.67 in the prior period, reflecting a significant increase[78] - Cash outflow from financing activities amounted to $990,189,051.81, up from $460,883,663.95 in the previous year[78] - Net cash flow from financing activities was $122,763,070.89, a decrease from $353,982,841.72 year-over-year[78] - Cash received from borrowings was $1,112,216,128.41, an increase from $814,866,505.67 in the prior year[78] - Cash paid for debt repayment was $956,496,784.74, significantly higher than $436,316,371.62 in the previous period[78]

Financial Performance - The net profit attributable to shareholders decreased by 63.98% year-on-year, primarily due to an increase in government subsidies compared to the previous year[33]. - The net cash flow from operating activities increased by 56.71% year-on-year, mainly due to an increase in government subsidies received and tax refunds from national preferential policies[34]. - The company plans not to distribute cash dividends or bonus shares, nor to increase capital from reserves[16]. - The company reported a significant decline in pharmaceutical service revenue, leading to an increase in asset impairment provisions[33]. - The net profit attributable to shareholders in the fourth quarter significantly decreased compared to the previous three quarters due to the full impairment provision for R&D projects that could not meet expectations[37]. - The net profit excluding non-recurring gains and losses in the fourth quarter also saw a substantial decline, primarily due to government subsidies received during the quarter[37]. - Government subsidies recognized in the current period amounted to approximately ¥130.05 million, which is a key factor in the financial results[39]. - The total net profit after tax and minority interests for the fourth quarter was approximately ¥111.91 million, reflecting the impact of the aforementioned factors[39]. - The company’s operating revenue for 2022 was ¥3,836,640,799.74, a decrease of 12.98% compared to ¥4,409,035,585.85 in 2021[51]. - The net profit attributable to shareholders for 2022 was ¥191,277,350.92, down 31.29% from ¥278,398,951.02 in 2021[51]. - The net profit after deducting non-recurring gains and losses was ¥79,371,328.72, a decline of 63.98% compared to ¥220,375,153.57 in 2021[51]. - The net cash flow from operating activities increased by 56.71% to ¥472,065,141.66 in 2022, up from ¥301,231,402.96 in 2021[51]. - The total assets at the end of 2022 were ¥12,543,503,416.06, reflecting a 3.11% increase from ¥12,165,124,976.56 at the end of 2021[51]. - The net assets attributable to shareholders increased by 3.24% to ¥8,811,484,555.00 at the end of 2022, compared to ¥8,535,174,993.28 at the end of 2021[51]. - The company reported a basic earnings per share of ¥0.16 for 2022, down 30.43% from ¥0.23 in 2021[51]. - The weighted average return on equity for 2022 was 2.20%, a decrease of 1.08% from 3.28% in 2021[51]. Risk Management - The company has identified various risks in its operations, including R&D underperformance, goodwill impairment, exchange rate fluctuations, international business risks, and safety and environmental risks[5]. - The company has not experienced any substantial risks that could significantly impact its production and operations during the reporting period[5]. - The company emphasizes the importance of understanding the differences between plans, forecasts, and commitments in its future development statements[11]. Research and Development - The company is focusing on R&D projects, including the development of new products such as F-627 and F-652, which are currently under research[43]. - The company aims to leverage innovation to meet unmet clinical needs and enhance international competitiveness in the pharmaceutical sector[85]. - The company will adopt a cooperative and self-research approach for new product development, emphasizing innovation-driven strategies and green manufacturing initiatives[102]. - The company is committed to pursuing high-quality sustainable development by focusing on patient needs and avoiding homogenized competition in drug development[102]. - The company will focus on key traditional Chinese medicine products, enhancing development and academic construction to elevate product academic status and transition to mass branding[95]. - The company aims to strengthen its innovation capabilities in synthetic biology technology through collaboration with research institutions and self-built R&D teams, aligning with global trends[97]. - The company has improved its procurement system for core Chinese medicinal materials and key raw materials, ensuring optimal supplier performance in price, quality, and service[108]. - The company has established a complete independent system for R&D, procurement, production, and sales based on market demand and its actual situation[108]. - The company’s new product development is primarily based on independent R&D, supplemented by collaborations with overseas and domestic research institutions[112]. Market Position and Strategy - The company holds a leading position in the vitamin B5 market, with over 70% of its sales directed to Europe and the United States[69]. - The company plans to continue its market expansion and strategic acquisitions to enhance its competitive position in the pharmaceutical industry[43]. - The company is one of the few domestic firms to submit new drug applications for the same product simultaneously in the US, Europe, and China, indicating strong market positioning[88]. - The company has a high global market share in raw material drugs, with over 70% of Vitamin B5 products sold to Europe and the US, maintaining a leading position[88]. - The company’s sales strategy for the product Aibegesitin α injection mainly involves external authorization, receiving milestone payments and net sales royalties[110]. - The company’s core Chinese medicine products and key chemical drug products are produced based on market sales conditions and product demand plans[108]. Environmental Compliance - The company has established a comprehensive emergency response mechanism for environmental pollution incidents and has conducted multiple drills to enhance emergency handling capabilities[173]. - The company has achieved compliance in all monitored environmental discharge parameters, including wastewater and air emissions, with specific values such as 19.7 mg/L for biochemical oxygen demand and 8.5 mg/m³ for particulate matter[171]. - The company has implemented a "2022 Employee Stock Ownership Plan" to motivate and retain talent, alongside a comprehensive employee benefits system[177]. - The company has made significant investments in pollution control facilities, including a rotary kiln incinerator and a sludge dewatering machine, to ensure compliance with environmental regulations[171]. - The company has maintained transparency in information disclosure, enhancing communication with investors through various channels[176]. - The company has no recorded violations or penalties during the reporting period, indicating a strong compliance record[174]. - The company reported that it continues to meet environmental discharge standards for its operations[191]. - The company has established online monitoring systems for wastewater and air emissions, with data automatically uploaded to environmental authorities, ensuring compliance with national monitoring regulations[198]. - In 2022, all self-monitoring and supervisory monitoring results were compliant, demonstrating the company's effective pollution management capabilities[198]. - The company is actively conducting annual carbon emission audits to guide energy-saving measures across departments, aiming to reduce overall energy consumption[199]. Employee and Governance - The total number of employees is 4,338, with 1,092 in sales, 849 in technical roles, and 178 in finance[145]. - The company has implemented a training program for employees, focusing on various levels and roles to enhance skills and performance[146]. - The company’s governance structure includes various committees that have met multiple times to discuss performance evaluations and compensation plans[143]. - The company has a total of 36 employees with a PhD, 213 with a master's degree, and 1,278 with a bachelor's degree, indicating a strong educational background among staff[145]. - The employee stock ownership plan purchased a total of 7,292,100 shares, accounting for 0.59% of the company's total share capital, at an average price of RMB 10.765 per share, totaling approximately RMB 78.5 million[157]. - The company has implemented a dynamic management approach for its R&D projects, increasing investment in key products[138]. - The company plans to enhance its governance structure and internal control systems to improve operational compliance and investor relations[189].

现场参与地点：安徽省合肥市肥西县桃花镇繁华大道与文山路交口，合肥亿 帆生物制药有限公司一楼会议室。 亿帆医药股份有限公司（以下简称"公司"）于2023年4月15日在巨潮资讯 网上披露了《2022年年度报告》，为了让广大投资者更深入全面地了解公司经营 管理、发展战略、行业前景等情况，公司将举行2022年度业绩说明会，具体安排 如下： 一、说明会时间、地点和形式 股票代码：002019 股票简称：亿帆医药 公告编号：2023-030 亿帆医药股份有限公司 关于举行 2022 年度业绩说明会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要事项提示： 会议时间：2023年6月2日（周五） 13:00-15:00 会议形式：现场参与+网络视频直播 欢迎广大投资者积极参与本次网上说明会。 （问题征集二维码） 召开时间：2023年6月2日（周五）13:00-15:00 召开形式：现场参与+网络视频直播 本次业绩说明会将采用"现场参与+网络视频直播"的方式实现线上线下同 步进行。线下会场设在安徽省合肥市肥西县桃花镇繁华大道与文山路交口，合肥 亿帆生物制药有限公司一 ...

Financial Performance - Revenue for Q3 2022 was ¥959,518,634.11, a decrease of 5.94% year-over-year, and a total revenue of ¥2,728,866,329.74 for the year-to-date, down 19.68% compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2022 was ¥42,696,040.25, a decline of 45.00% year-over-year, with year-to-date net profit of ¥203,256,070.64, down 30.10%[3]. - The net profit after deducting non-recurring gains and losses for Q3 2022 was ¥24,925,435.23, a decrease of 62.08% year-over-year, and year-to-date was ¥130,283,488.50, down 47.89%[3]. - The company reported a significant decrease in pharmaceutical service revenue, which contributed to the decline in net profit[3]. - The company reported a net profit margin decline due to reduced operating revenue and increased costs, impacting overall profitability[22]. - The total revenue for Q3 2022 was approximately 753.19 million, an increase from 607.22 million in Q3 2021, representing a growth of about 24%[24]. - The net profit for Q3 2022 was approximately 150.26 million, down from 242.33 million in Q3 2021, indicating a decrease of about 38%[24]. - Operating profit for Q3 2022 was approximately 186.75 million, compared to 277.14 million in Q3 2021, reflecting a decline of about 33%[24]. - The basic earnings per share for Q3 2022 was 0.16, compared to 0.24 in Q3 2021, a decline of about 33%[25]. - The total comprehensive income attributable to the parent company's owners for Q3 2022 was approximately 196.35 million, compared to 204.24 million in Q3 2021, a decrease of about 4%[25]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥12,693,749,219.29, an increase of 4.35% from the end of the previous year[3]. - Total assets increased to approximately $12.69 billion, up from $12.17 billion year-over-year, reflecting a growth of about 4.3%[21]. - Total liabilities rose to approximately $3.57 billion, compared to $3.39 billion in the previous year, indicating an increase of about 5.5%[21]. - Non-current assets totaled approximately $8.77 billion, an increase from $8.58 billion, showing a growth of about 2.2%[21]. Cash Flow - The company’s cash flow from operating activities for the year-to-date was ¥273,207,235.15, a decrease of 16.68% compared to the previous year[3]. - Cash flow from operating activities for Q3 2022 was approximately 273.21 million, down from 327.90 million in Q3 2021, a decrease of about 17%[27]. - Cash flow from investment activities showed a net outflow of approximately 400.31 million in Q3 2022, compared to a net outflow of 659.89 million in Q3 2021, improving by about 39%[27]. - The company’s cash and cash equivalents stood at approximately $1.32 billion, slightly down from $1.34 billion[19]. - The cash and cash equivalents at the end of Q3 2022 amounted to approximately 1.10 billion, an increase from 710.12 million at the end of Q3 2021[27]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 52,006[9]. - The largest shareholder, Cheng Xianfeng, holds 40.50% of the shares, totaling 496,526,307 shares, with 66,500,000 shares pledged[9]. - The top ten shareholders hold a total of 124,131,577 unrestricted shares[12]. - Cheng Xianfeng's unrestricted shares amount to 124,131,577, while Hong Kong Central Clearing Limited holds 19,077,392 unrestricted shares[12]. - The company has not identified any other related party relationships among shareholders beyond those disclosed[13]. Government Support and Investments - The company received government subsidies amounting to ¥80,146,605.63 year-to-date, which is an increase of 134.61% compared to the previous year[8]. - Evive Biotech Ltd. plans to issue common stock at $7.2225 per share, with Sino Biopharmaceutical Limited investing $20 million for 2,769,132 shares and committing to invest at least $10 million in future financing[18]. - The total investment from Yifan Pharmaceutical (Hong Kong) Co., Ltd. amounts to $50 million for 6,922,831 shares, bringing the total investment in Evive to $70 million[18]. Operational Changes - The company’s long-term borrowings increased by 40.94% to ¥1,029,599,250.26 due to adjustments in financing structure[7]. - The company reported a 34.12% decrease in operating costs year-to-date, totaling ¥1,331,405,844.19, primarily due to reduced promotional service costs[8]. - The company completed the registration capital change, reducing it from RMB 1,234,106,077 to RMB 1,226,024,827[17]. - The employee stock ownership plan raised RMB 78.5 million, with 70 participants, and purchased 3,960,900 shares at an average price of approximately RMB 10.192 per share[15]. - The company has implemented a stock repurchase plan for restricted stock from 2019, with completion reported on July 29, 2022[14]. Regulatory Approvals - The company’s subsidiary received a drug registration certificate for lactulose oral solution on August 17, 2022[16]. - The company’s subsidiary obtained a registration approval for traditional Chinese medicine from the Singapore Health Sciences Authority in September 2022[16].

Financial Performance - Yifan Pharmaceutical's financial report is guaranteed to be true, accurate, and complete by its management team[2]. - The company's revenue for the first half of 2022 was CNY 1,769,347,695.63, a decrease of 25.58% compared to CNY 2,377,403,852.30 in the same period last year[13]. - Net profit attributable to shareholders for the same period was CNY 160,560,030.39, down 24.67% from CNY 213,141,089.54 year-on-year[13]. - The net profit after deducting non-recurring gains and losses was CNY 105,358,053.27, representing a decline of 42.82% compared to CNY 184,269,117.63 in the previous year[13]. - The net cash flow from operating activities was CNY 183,810,575.85, a decrease of 18.71% from CNY 226,113,089.99 in the same period last year[13]. - Basic earnings per share were CNY 0.13, down 23.53% from CNY 0.17 in the previous year[13]. - Total assets as of June 30, 2022, were CNY 12,475,973,066.21, an increase of 2.56% from CNY 12,165,124,976.56 at the end of the previous year[13]. - Net assets attributable to shareholders were CNY 8,628,473,676.89, up 1.09% from CNY 8,535,174,993.28 at the end of the previous year[13]. - The company reported a total non-operating income of ¥55,201,977.12, primarily due to the write-off of uncollectible amounts during the reporting period[17]. - The company achieved a revenue of CNY 1,769.35 million in the first half of 2022, a decrease of 25.58% compared to the same period last year[36]. Risk Management - The company has not identified any significant risks impacting its operations during the reporting period[2]. - The management highlighted various potential risks including COVID-19, R&D underperformance, and international operational risks[2]. - The company has a comprehensive risk management strategy in place to address various operational challenges[2]. - The company faces risks from the ongoing COVID-19 pandemic, which may adversely affect overseas R&D, production, sales, and supply chain construction[69]. - The company is exposed to risks related to drug development not meeting expectations, including the potential for clinical trial failures and the conversion of capitalized development expenses to operating expenses[70]. - The company is addressing performance volatility risks due to fluctuating prices of key products like Vitamin B5, aiming to enhance pharmaceutical business performance[72]. - The company is adapting to centralized procurement policies that may pressure drug prices and affect domestic sales, while increasing the proportion of international revenue[73]. - The company is closely monitoring exchange rate fluctuations, which have significantly impacted profitability due to mismatched foreign currency assets and liabilities[75]. - The company plans to enhance risk management by optimizing foreign currency allocation and utilizing financial instruments to hedge against exchange rate risks[76]. - International operations are facing risks from geopolitical tensions, particularly the ongoing US-China trade disputes, which may affect revenue and profit from overseas businesses[77]. Research and Development - The company is focused on expanding its market presence and enhancing its product offerings through R&D[2]. - The company is committed to ongoing research and development in the pharmaceutical sector to drive future growth[18]. - The company completed the registration of three products and submitted three new drug applications during the reporting period, with a total of 51 projects still under development[43]. - The company has established partnerships for the sale of certain products, enhancing its market reach and distribution capabilities[19]. - The F-627 product, aimed at treating chemotherapy-induced neutropenia, has received regulatory acceptance in China and is undergoing clinical trials in multiple regions[37]. Market Conditions - The pharmaceutical industry is entering a new phase of high-quality development, driven by innovation and modernization of the industrial chain, but is facing challenges such as declining profits and market growth slowing down[23]. - In the first half of 2022, the pharmaceutical manufacturing industry achieved revenue of CNY 1,400.78 billion, a year-on-year decline of 0.6%, which is 9.7 percentage points lower than the overall level of large-scale industrial enterprises[23]. - The total profit of the pharmaceutical manufacturing industry in the first half of 2022 was approximately CNY 220.95 billion, down 27.6% year-on-year, which is 28.6 percentage points lower than the overall level of large-scale industrial enterprises[23]. - The vitamin industry is experiencing a decline in market conditions due to oversupply, weak terminal consumption growth, and disordered competition among small manufacturers[25]. - The company’s main products, vitamin B5 and its derivatives, are crucial in the vitamin market, which is largely driven by animal nutrition and food additives[26]. Environmental Compliance - The company is committed to adhering to local environmental standards and enhancing safety measures in response to global carbon emission policies[78]. - The company achieved a compliance rate of 100% across all monitored pollutants in the reporting period[87][88]. - The company has implemented effective pollution prevention facilities, ensuring operational compliance with environmental regulations[88]. - The wastewater treatment facility has a processing capacity of 3,000 t/d and has been in operation since November 2002, with stable performance[89]. - The company has established a comprehensive emergency response mechanism for environmental pollution incidents, with multiple drills conducted to enhance emergency handling capabilities[95]. Shareholder Information - Yifan Pharmaceutical reported no cash dividends or stock bonuses for the period[3]. - The company has not reported any significant impairment risks for its overseas assets[53]. - The company has not engaged in any related party transactions during the reporting period[103]. - The company has maintained a clean record with no non-operating fund occupation by major shareholders or related parties[101]. - The total number of ordinary shareholders at the end of the reporting period was 48,451, representing 5% of the total shares[124].

Financial Performance - The company's revenue for Q1 2022 was ¥905,920,591.79, a decrease of 24.53% compared to ¥1,200,337,373.23 in the same period last year[2] - Net profit attributable to shareholders was ¥121,266,909.58, down 8.30% from ¥132,244,842.10 year-on-year[2] - The net profit after deducting non-recurring gains and losses was ¥76,821,416.28, reflecting a significant decline of 31.90% from ¥112,814,160.06 in the previous year[3] - The total profit for Q1 2022 was approximately ¥135.57 million, a decrease of 8.5% compared to ¥147.57 million in Q1 2021[22] - The net profit attributable to the parent company was approximately ¥121.27 million, down from ¥132.24 million, representing a decline of 8.3% year-over-year[22] - The company's net profit for Q1 2022 was CNY 124,239,046.87, a decrease of 7.9% compared to CNY 134,304,706.57 in Q1 2021[21] - The company's total comprehensive income for Q1 2022 was approximately ¥89.54 million, down from ¥114.53 million in Q1 2021, indicating a decline of 21.8%[22] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥46,018,343.12, a drastic decrease of 130.90% compared to ¥148,929,731.56 in the same period last year[4] - The operating cash flow for Q1 2022 was negative at approximately -¥46.02 million, compared to a positive cash flow of ¥148.93 million in the same period last year[23] - Total cash inflow from operating activities was approximately ¥1.01 billion, a decrease of 17.2% from ¥1.22 billion in Q1 2021[23] - The company reported a net cash outflow from investing activities of approximately -¥145.91 million, an improvement from -¥217.93 million in Q1 2021[24] - Cash and cash equivalents at the end of Q1 2022 totaled approximately ¥1.02 billion, slightly down from ¥1.03 billion at the end of Q1 2021[24] - The company's cash and cash equivalents increased to CNY 1,500,808,136.01 from CNY 1,336,143,759.93 at the beginning of the year, representing a growth of 12.3%[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥12,499,765,833.99, representing a 2.75% increase from ¥12,165,124,976.56 at the end of the previous year[3] - The total assets of the company reached CNY 12,499,765,833.99, an increase from CNY 12,165,124,976.56 at the beginning of the year, marking a growth of 2.7%[20] - The total liabilities increased to CNY 3,622,045,879.06 from CNY 3,390,566,493.65, representing a rise of 6.8%[20] Shareholder Information - The top shareholder, Cheng Xianfeng, holds 40.23% of the shares, amounting to 496,526,307 shares[10] - The second-largest shareholder, Hong Kong Central Clearing Limited, holds 1.65% of the shares, totaling 20,370,446 shares[10] - Cheng Xianfeng and several investment funds are identified as acting in concert, indicating a coordinated shareholder strategy[12] - The top ten shareholders hold a total of 124,131,577 shares of common stock, representing a significant portion of the company's equity[11] Operating Costs and Expenses - The company's gross profit margin decreased due to a shift in revenue structure, with a 40.76% reduction in operating costs to ¥427,472,846.50 from ¥721,608,037.10[8] - Total operating costs for Q1 2022 were CNY 815,202,981.81, down 23.5% from CNY 1,065,298,825.32 in Q1 2021[21] - Financial expenses surged by 388.98% to ¥21,742,252.26, primarily due to increased interest expenses and foreign exchange losses[8] - Research and development expenses for Q1 2022 were CNY 38,302,629.24, slightly down from CNY 40,513,368.64 in the previous year[21] Product Development and Licensing - The company received drug registration certificates for multiple products, including Ammonium Bromide Injection on January 7, 2022[14] - The company signed an exclusive licensing agreement for the product F-627 with Apogepha Arzneimittel GmbH, involving a non-refundable advance of $400,000 and potential milestone payments up to $37.5 million[17] - The company’s subsidiary, Hefei Yifan Biopharmaceutical Co., received a registration acceptance notice for Dopamine Hydrochloride Injection on January 11, 2022[14] - The company’s subsidiary, Liao Ning Yifan Pharmaceutical Co., received a registration acceptance notice for Tirofiban Hydrochloride Injection on January 24, 2022[14] - The company’s subsidiary, Yifan You Sheng Mei Te Pharmaceutical Technology Co., passed the consistency evaluation for Cefuroxime Sodium Injection[15] Stock and Incentives - The company has initiated a stock incentive plan, with the second vesting period approved on January 4, 2022[13] - Basic earnings per share for Q1 2022 were ¥0.10, compared to ¥0.11 in Q1 2021, reflecting a decrease of 9.1%[23] - The weighted average return on net assets was 1.41%, down from 1.55% in the previous year[3] - The company recorded other comprehensive income after tax of approximately -¥14.91 million, worsening from -¥3.69 million in the previous year[22]

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the year 2021, representing a year-over-year increase of 15%[9]. - The net profit for 2021 was 200 million RMB, which is a 10% increase compared to the previous year[9]. - The company's operating revenue for 2021 was ¥4,409,035,585.85, a decrease of 18.36% compared to 2020[14]. - The net profit attributable to shareholders for 2021 was ¥278,398,951.02, down 71.25% from the previous year[14]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥220,375,153.57, a decline of 74.41% year-over-year[14]. - The diluted earnings per share for 2021 was ¥0.23, down 70.89% from ¥0.79 in 2020[15]. - The total assets at the end of 2021 were ¥12,165,124,976.56, an increase of 4.54% from the end of 2020[15]. - The net assets attributable to shareholders at the end of 2021 were ¥8,535,174,993.28, up 1.13% from the previous year[15]. - The company achieved operating revenue of 440,903.56 million yuan, a decrease of 18.36% year-on-year, and net profit attributable to shareholders of 27,839.90 million yuan, down 71.25% year-on-year[63]. Revenue Guidance and Growth Targets - The company has set a revenue guidance of 1.5 billion RMB for 2022, indicating a growth target of 25%[9]. - The company reported a significant decline in net profit in Q4 2021, primarily due to goodwill impairment testing and decreased revenue from pharmaceutical services[18]. - The company plans to explore potential mergers and acquisitions to strengthen its market position in the pharmaceutical industry[8]. Research and Development - New product F-627, an injectable drug, is currently in the research phase and is expected to enter clinical trials in 2022[8]. - The company has invested 50 million RMB in R&D for new technologies in 2021, focusing on innovative drug delivery systems[8]. - The company has established a dual-molecule research platform, DiKineTM, to develop innovative biopharmaceuticals for the global market[60]. - The company is developing innovative drugs for the overseas market, with projects F-627 and F-652 having completed clinical trials and submitted for approval in multiple regions[92]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, with plans to establish partnerships in three new countries by the end of 2022[8]. - The company has signed commercialization cooperation agreements in China, Greece, Cyprus, and Germany, expanding its market presence[63]. - The company is actively pursuing new product registrations and has submitted applications for four new generic drugs to the US FDA[67]. Risks and Challenges - The company has outlined various risks that may impact its operations, including COVID-19, research and development underperformance, and international business risks[2]. - The company acknowledges the risk of research and development projects not meeting expectations, which could lead to financial losses if clinical trials fail or are delayed[133]. - The company is addressing the risk of performance volatility in its Vitamin B5 product line due to market competition and supply-demand dynamics, while also expanding its pharmaceutical business[134]. Environmental Management - The company is committed to environmental management and pollution control, aligning with national policies on carbon peak action and green development[40]. - The wastewater treatment facility has a processing capacity of 3,000 tons per day and has been in operation since November 2002, with stable performance[198]. - The company has implemented pollution control facilities for both wastewater and flue gas, ensuring compliance with environmental standards[198]. Corporate Governance - The company has established a robust internal control system, revising over 20 regulations to enhance governance and operational standards[146]. - The company emphasizes strict compliance with laws and regulations regarding related transactions and significant investments[194]. - The company has maintained a clear separation from its controlling shareholder in both operational and financial aspects, with no interference in fund usage[148]. Employee Management - The employee compensation structure includes fixed salaries, performance bonuses, and benefits, aimed at enhancing employee satisfaction and loyalty[176]. - The company has conducted various training programs for employees, focusing on skill enhancement and organizational performance improvement[177]. - The total number of employees at the end of the reporting period was 4,285, with 60 in the parent company and 4,225 in major subsidiaries[175]. Product Portfolio - Key products include Zometa for treating bone damage in cancer patients and Thymosin α1 for immune modulation in cancer and hepatitis treatment, with both domestic and international sales strategies[42]. - The company has a total of 336 approved drug products domestically, with 41 exclusive varieties, highlighting its diverse product portfolio[58]. - The company’s vitamin B5 products are marketed globally as essential additives in feed and food industries[45]. Financial Management - The company has implemented a centralized management platform for overseas funds, enhancing the efficiency of domestic and international fund flows[75]. - The company reported a financial liability of ¥28,631.90 at the end of the reporting period, with an increase of ¥6,936.77 during the period[102]. - The company has not engaged in any related party transactions that would involve the controlling shareholder misusing company funds[148].

Financial Performance - The company's revenue for Q3 2021 was ¥1,020,118,230.77, a decrease of 23.39% compared to the same period last year[3]. - Net profit attributable to shareholders was ¥77,622,349.17, down 59.76% year-on-year[3]. - The net profit after deducting non-recurring gains and losses was ¥65,726,125.51, reflecting a decline of 64.38% compared to the previous year[3]. - The basic earnings per share for the period was ¥0.06, a decrease of 62.50% year-on-year[3]. - Total operating revenue for Q3 2021 was ¥3,397,522,083.07, a decrease of 17.9% compared to ¥4,142,231,771.86 in the same period last year[25]. - Net profit for Q3 2021 was ¥242,333,816.18, down 72.6% from ¥884,551,785.31 in Q3 2020[26]. - Earnings per share (EPS) for Q3 2021 was ¥0.24, compared to ¥0.74 in the same quarter last year[27]. - The company's total comprehensive income for Q3 2021 was ¥204,241,290.93, significantly lower than ¥870,206,230.11 in Q3 2020[27]. Assets and Liabilities - Total assets at the end of the reporting period were ¥11,977,316,407.73, an increase of 2.92% from the end of the previous year[4]. - Total liabilities amounted to ¥11,977,316,407.73, an increase from ¥11,637,239,651.30 year-over-year[24]. - Total equity reached ¥8,878,539,248.40, up from ¥8,730,227,226.07 in the previous year[24]. - The total assets increased to ¥11,708,097,760.68 from ¥11,637,239,651.30, reflecting a growth of approximately 0.61%[30]. - The total liabilities increased, with short-term borrowings remaining at ¥1,193,086,922.56, unchanged from the previous period[30]. - Total liabilities amounted to CNY 2,907,012,425.23, a decrease of CNY 83,837,192.14 from the previous quarter[31]. - Current liabilities totaled CNY 2,128,945,704.81, reflecting a decrease of CNY 13,481,600.17 compared to the previous quarter[31]. - Non-current liabilities decreased to CNY 778,066,720.42, down by CNY 70,355,591.97 from the previous quarter[31]. Cash Flow - The company reported a net cash flow from operating activities of ¥327,901,225.80, a decrease of 69.88% year-to-date[3]. - Cash flow from operating activities decreased by 69.88% to ¥327,901,225.80, mainly due to reduced cash inflow from sales of goods[10]. - Operating cash flow for the period was ¥327,901,225.80, a decrease of 69.9% compared to ¥1,088,478,560.76 in the previous period[28]. - Cash inflow from investment activities was ¥1,240,000,000.00, up from ¥1,015,000,000.00 in the previous period, while cash outflow was ¥1,921,724,244.94, compared to ¥1,604,391,097.40 previously, resulting in a net cash flow from investment activities of -¥659,887,548.59[29]. - Total cash inflow from financing activities was ¥2,248,099,792.61, an increase from ¥1,942,209,194.94 in the previous period, while cash outflow was ¥2,063,991,064.16, slightly down from ¥2,099,354,004.62, leading to a net cash flow from financing activities of ¥184,108,728.45[29]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 53,388[11]. - The largest shareholder, Cheng Xianfeng, holds 40.23% of the shares, amounting to 496,526,307 shares[11]. - The company plans to repurchase shares with a budget between RMB 100 million and RMB 150 million, with a maximum repurchase price of RMB 21.88 per share[20]. - As of September 30, 2021, the company had repurchased a total of 4,826,442 shares, accounting for 0.39% of the total share capital, with a total expenditure of approximately RMB 80.69 million[21]. Operational Highlights - Sales expenses increased by 30.33% to ¥607,223,802.44 compared to the same period last year, primarily due to increased promotion of proprietary and imported pharmaceutical products[9]. - Investment income decreased by 112.89% to -¥8,652,029.04, mainly due to increased investment losses from joint ventures[9]. - Operating profit dropped by 74.21% to ¥277,135,721.74, attributed to a significant decline in the price of vitamin B5 in the raw material drug sector[9]. - Net profit attributable to shareholders decreased by 68.09% to ¥290,763,438.71, driven by lower gross profit and increased sales expenses[9]. - Research and development expenses for Q3 2021 were ¥132,958,645.93, a decrease of 11% from ¥149,383,056.45 in Q3 2020[26]. Regulatory and Compliance - The company has implemented a stock incentive plan, with the second unlock period for restricted stock completed as of June 24, 2021[15]. - The company received a registration acceptance notice for the overseas production of cross-linked sodium hyaluronate injection (brand name: Hyruan ONE®) on July 21, 2021[17]. - The company’s subsidiary received a registration acceptance notice for chlorpromazine injection on August 2, 2021[17]. - Shanghai Yiyi obtained approval for a Phase II clinical trial for the product F-652 for the indication of acute liver failure on September 7, 2021[18]. - A commercialization cooperation agreement was signed on August 26, 2021, granting exclusive licensing of F-627's intellectual property rights in China to Zhengda Tianqing Pharmaceutical Group[19]. Future Outlook - The company plans to focus on expanding its market presence and investing in new technologies to drive future growth[29].

Financial Performance - The company's operating revenue for the first half of 2021 was ¥2,377,403,852.30, a decrease of 15.41% compared to the same period last year[14]. - The net profit attributable to shareholders was ¥213,141,089.54, down 70.33% year-on-year[14]. - The net profit after deducting non-recurring gains and losses was ¥184,269,117.63, a decline of 73.71% compared to the previous year[14]. - The net cash flow from operating activities was ¥226,113,089.99, representing a decrease of 69.74% from the same period last year[14]. - The basic earnings per share for the reporting period were ¥0.17, a decrease of 70.69% compared to the same period last year[14]. - In the first half of 2021, the company achieved operating revenue of CNY 237,740.39 million, a decrease of 15.41% year-on-year, and net profit attributable to shareholders of CNY 21,314.11 million, down 70.33% year-on-year[31]. - The company reported a net profit distribution of -125,267,707.70 yuan for the current period[161]. - The total comprehensive income for the first half of 2021 was ¥766,541.51, compared to ¥905,567,609.04 in the previous year, indicating a similar decline[150]. Assets and Liabilities - The total assets at the end of the reporting period were ¥12,022,307,739.56, an increase of 3.31% compared to the end of the previous year[14]. - The net assets attributable to shareholders at the end of the reporting period were ¥8,623,633,796.89, up 2.18% from the previous year[14]. - Total liabilities amounted to CNY 3,155,234,713.71, up from CNY 2,907,012,425.23, marking an increase of around 8.54%[140]. - The company's equity attributable to shareholders increased to CNY 8,623,633,796.89 from CNY 8,439,869,309.79, representing a growth of about 2.18%[140]. - Cash and cash equivalents at the end of the reporting period amounted to ¥1,439,518,912.17, which is 11.97% of total assets, an increase from 11.38% in the previous year[50]. - Accounts receivable increased to ¥1,104,268,379.72, making up 9.19% of total assets, up from 8.64% year-on-year[50]. - The company’s inventory stood at ¥632,061,306.80, representing 5.26% of total assets, compared to 5.02% in the previous year[50]. Risks and Challenges - The company has detailed various risks it may face, including performance volatility, COVID-19 risks, goodwill impairment risks, and international operational risks[2]. - The ongoing COVID-19 pandemic poses risks to the company's overseas R&D, production, and sales, potentially impacting overall performance[61]. - The company faces risks related to performance fluctuations due to the declining market price of Vitamin B5, which has been affected by supply and demand since June 2020[60]. - The company is exposed to foreign exchange risks due to significant overseas operations, necessitating the implementation of a robust currency management mechanism[63]. - The company is actively monitoring international trade tensions, particularly between China and the U.S., which could affect its overseas business operations[64]. Research and Development - The company completed the IND application for new drug F-899 and initiated Phase I clinical trials, marking progress in its R&D pipeline[32]. - The company’s growth strategy includes expanding its product offerings in the fields of oncology and immunology[22]. - The company emphasizes the importance of its imported products, which include key medications for critical conditions[22]. - The company’s focus on research and development aims to enhance its product efficacy and market reach[22]. - R&D investment rose by 25.46% to CNY 278,125,651.23, indicating a focus on innovation[42]. Environmental Compliance - The company reported a total COD discharge of 4.22 tons, which is within the approved limit of 35.56 tons[73]. - The company achieved a nitrogen oxide (NOx) discharge of 1.522 tons, well below the approved limit of 17.06 tons[73]. - The company’s wastewater treatment facility has a processing capacity of 3,000 tons per day and has been operating stably since November 2002[75]. - The company’s air pollution control systems utilize advanced technologies such as SNCR and SCR for effective emissions treatment, ensuring compliance with environmental standards[79]. - The company has successfully passed environmental impact assessments and completion inspections from relevant environmental protection authorities in their operational regions[80]. Corporate Governance - The company is actively enhancing its governance structure and internal controls to improve operational management and risk prevention capabilities[39]. - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[90]. - There were no significant lawsuits or arbitration matters during the reporting period, with only minor cases pending[92]. - The company has not experienced any penalties or rectification issues during the reporting period[93]. - The half-year financial report was not audited[91]. Shareholder Information - The total number of shares decreased by 571,000, resulting in a total share count of 1,234,106,077[120]. - The largest shareholder, Cheng Xianfeng, holds 40.23% of the shares, totaling 496,526,307[125]. - The company approved the release of 2,392,000 restricted shares for 59 individuals on January 13, 2021[122]. - The number of foreign shareholders decreased by 12,543,012 shares during the reporting period[125]. - The total number of common shareholders at the end of the reporting period was 57,714[125].